Scisparc management commentary says H1 2026 operating loss widens to USD 4.89 million on higher R&D, G&A costs

• Management commentary from Scisparc covered the six months ended June 30, 2026, with revenue falling to USD 284,000 from USD 461,000.
• Operating loss widened to USD 4.89 million as higher R&D and G&A spending outweighed lower sales, marketing, and distribution costs.
• R&D expense rose to USD 1.58 million, driven by higher wages, share-based compensation, and increased clinical activity.
• G&A increased to USD 3.2 million, led by higher share-based compensation and wages, partly offset by slightly lower professional fees.
• Cash totaled USD 4.46 million, with management flagging it as insufficient for at least one year without additional financing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-105319), on September 30, 2026, and is solely responsible for the information contained therein.